Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $62.1667.

SUPN has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Stifel Nicolaus lifted their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th.

Insider Activity at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,185 shares of company stock worth $1,268,022 in the last 90 days. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares in the last quarter. Torren Management LLC bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth $49,000. USA Financial Formulas bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth $50,000. Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the period. Finally, Global Retirement Partners LLC increased its stake in shares of Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 1,182 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $53.87 on Monday. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $59.68. The firm has a 50-day simple moving average of $50.99 and a two-hundred day simple moving average of $48.82. The company has a market cap of $3.10 billion, a P/E ratio of -79.22, a PEG ratio of 1.67 and a beta of 0.70.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.